My Blue Dots

VANCOUVER, British Columbia & DALLAS–(BUSINESS WIRE)–Alpha Cognition, Inc. (Nasdaq: ACOG) (“ACI” or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, and China Medical System Holdings Limited (CMS) (867.HK), a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability in the People’s Republic of China, today announced an exclusive licensing agreement for the

CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms across cancer types. Clinical care for cancer patients is hindered by insufficient biomarkers that fail to accurately predict patient response to treatment.

SAN FRANCISCO & SEATTLE–(BUSINESS WIRE)– #HealthWayFinding–Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and primary care, announced that they have entered into a definitive agreement under which Transcarent will acquire Accolade for $7.03 per share in cash, which represents a total equity value of approximately $621M. This strategic combination, which has been unanimously approved by the Boards of Directors of both companies, w

HAWTHORNE, Calif.–(BUSINESS WIRE)–OSI Systems, Inc. (the “Company” or “OSI Systems”) (NASDAQ: OSIS) today announced that its Security division received an order valued at approximately $23 million to assist in the deployment and integration of long-range radio frequency (RF) critical communication systems. As part of the award, the Company is expected to provide critical hardware as well as technical services designed to enhance the long-term availability of US government strategic RF communi

JACKSONVILLE, Fla.–(BUSINESS WIRE)–MMI will present in the private track at the 43rd J.P. Morgan Healthcare Conference, marking its 3rd year showcasing open surgery innovations.

BEIJING & ALAMEDA, Calif. & TAIPEI–(BUSINESS WIRE)–Biocytogen (HKEX: 02315) en Acepodia (6976:TT) hebben vandaag een baanbrekend strategisch partnerschap aangekondigd om gezamenlijk een programma voor dual-payload bispecifieke antilichaam-geneesmiddelconjugaten (BsAD2C) te beoordelen. Deze samenwerking combineert het RenLite®-platform van Biocytogen met de Antibody-Dual-Drugs Conjugation (AD2C)-technologie van Acepodia om enkele van de moeilijkste uitdagingen in de oncologie aan te pakken: tu

HOUSTON & CHICAGO–(BUSINESS WIRE)–CTMC, a joint venture between MD Anderson Cancer Center and Resilience, has entered a partnership with Syenex to advance the scalability and efficiency of engineered T cell therapies. Through this collaboration, CTMC will gain access to Syenex’s bioengineering systems, which provide a significant improvement in gene delivery efficiency and engineering timelines. Jason Bock, CEO of CTMC, stated, “Our mission is to accelerate the delivery of transformative cell

ST. LOUIS & HERCULES, Calif.–(BUSINESS WIRE)–Geneoscopy raises $105 million in Series C funding round, led by Bio-Rad Laboratories

COLUMBIA, Md.–(BUSINESS WIRE)–Propelled by historic expansion of its reach across diverse systems and state lines, CRISP Shared Services (CSS) today announced significant progress throughout 2024 toward its mission of providing localized and impactful health infrastructure and data exchange technology across the United States. CSS continued its impactful work with CRISP, Maryland’s state-designated health information exchange (HIE) and Health Data Utility (HDU); CRISP DC, serving the District

PECHINO, ALAMEDA, California e TAIPEI–(BUSINESS WIRE)–Biocytogen (HKEX: 02315) e Acepodia (6976:TT) oggi hanno annunciato l’inizio di una rivoluzionaria partnership strategica finalizzata a valutare congiuntamente un programma di sviluppo di coniugati farmaco-anticorpo bispecifico con doppio payload (BsAD2C). Questa collaborazione combina la piattaforma Biocytogen RenLite® con la tecnologia dei coniugati farmaco-anticorpo doppio (AD2C) Acepodia per risolvere alcuni dei problemi più complessi